English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the early 1990s, the vertebral axial decompression (VAX-D) spinal disc decompression therapy has been successfully implemented in the treatment of patients with low-back pain. Multiple clinical studies have demonstrated that this non-invasive treatment is an effective therapy for the management of low-back pain due to various pathologic conditions, including failed spinal surgery. The goal of this multi-center, international study was to both evidence and quantify the impact of the VAX-D therapy on the health-related quality of life (HRQL) in a sample of 105 patients, 49 male (average age 49.06 years) and 56 female (average age 48.23 years). These patients received a minimum of three, but usually not more than ten VAX-D treatment sessions of 20-30 min duration each, prior to being assessed for HRQL outcomes. Twelve HRQL assessment criteria were chosen through health careprovider and patient-selected input, related to pain intensity, personal care, lifting, walking sitting, standing, sleeping, sex life, social life, travel, job/home-duty performance, and range of motion -and incorporated in an AHP model using DecisionLens analytic hierarchy process (AHP) software. Our results demonstrate that this FDA-approved treatment has improved the overall HRQL in all patients, regardless of gender. The overall HRQL before treatment commenced was 0.432127 in males and 0.442481, on a ratio scale of 0-1, where 1 was the worst possible criteria assessment/outcome and 0 was the most positive. The overall HRQL after treatment ended was 0.0391147 (90.95% improvement) in males and 0.116742 (73.62% improvement) in females, the overall positive VAX-D effect being more pronounced in males. The VAX-D therapy improved the HRQL in all criteria categories, in both male and female patients. This provides evidence of significant personal and public-health benefits that this relatively low-cost, efficient treatment helps most patients with various low-back pain pathology and establishes it as a very valuable alternative to costly surgical low-back pain treatment whenever possible.

isahp proceedings

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE (HRQL) IN LOW-BACK PAIN PATIENTS BEFORE AND AFTER VAX-D DISC DECOMPRESSION TREATMENT. ANALYSIS USING THE COMPUTER- ASSISTED ANALYTIC HIERARCHY PROCESS (AHP)